Edition:
India

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

89.45USD
11 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$89.45
Open
$89.75
Day's High
$91.90
Day's Low
$87.65
Volume
202,702
Avg. Vol
301,939
52-wk High
$97.79
52-wk Low
$32.30

Latest Key Developments (Source: Significant Developments)

CRISPR Total Q2 Collaboration Revenue Was Less Than $0.1 Million
Tuesday, 28 Jul 2020 

July 27 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.CRISPR THERAPEUTICS AG - DOSING RE-INITIATED IN CLINICAL TRIALS OF CTX001™ FOR PATIENTS WITH SEVERE HEMOGLOBINOPATHIES.CRISPR THERAPEUTICS AG - CTX001 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR SICKLE CELL DISEASE.CRISPR THERAPEUTICS - EXPANDS REGENERATIVE MEDICINE PORTFOLIO THROUGH COLLABORATION WITH UNIVERSITY HEALTH NETWORK , GAINING ACCESS TO HEPATOCYTES.CRISPR THERAPEUTICS AG - EXPECT TO REPORT DATA FROM CTX001 PROGRAM TARGETING HEMOGLOBINOPATHIES & CTX110 PROGRAM LATER THIS YEAR.CRISPR THERAPEUTICS AG - CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2020 WERE $945.1 MILLION VERSUS $889.7 MILLION AS OF MARCH 31.CRISPR THERAPEUTICS AG - TOTAL COLLABORATION REVENUE WAS LESS THAN $0.1 MILLION FOR Q2 OF 2020 COMPARED TO $0.3 MILLION.CRISPR THERAPEUTICS AG - NET LOSS WAS $79.7 MILLION FOR Q2 OF 2020 COMPARED TO NET LOSS OF $53.7 MILLION.CRISPR THERAPEUTICS AG QTRLY LOSS PER SHARE $1.30.  Full Article

Crispr Therapeutics AG Says Public Offering Of 6.43 Million Common Shares Priced At $70.00 Per Share
Wednesday, 1 Jul 2020 

June 30 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 6.43 MILLION COMMON SHARES PRICED AT $70.00PER SHARE.  Full Article

Crispr Therapeutics Commencing Underwritten Public Offering Of $325 Mln Of Common Shares
Tuesday, 30 Jun 2020 

June 30 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AG - COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $325 MILLION OF COMMON SHARES.UNDERWRITERS WILL HAVE A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $48,750,000 OF COMMON SHARES AT THE PUBLIC OFFERING PRICE LESS THE UNDERWRITING DISCOUNT.OFFERING WILL BE MADE ONLY BY MEANS OF A PROSPECTUS.  Full Article

Crispr Therapeutics Reports First Quarter 2020 Financial Results
Wednesday, 29 Apr 2020 

April 28 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.CRISPR THERAPEUTICS AG - CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2020, WERE $889.7 MILLION.CRISPR THERAPEUTICS AG QTRLY TOTAL COLLABORATION REVENUE WAS $0.2 MILLION VERSUS $0.3 MILLION.CRISPR THERAPEUTICS AG QTRLY BASIC LOSS PER SHARE $1.15).CRISPR THERAPEUTICS AG - ENROLLMENT ONGOING IN CLINICAL TRIALS OF CTX001 FOR PATIENTS WITH SEVERE HEMOGLOBINOPATHIES.CRISPR THERAPEUTICS AG - ENROLLMENT ONGOING IN CLINICAL TRIAL OF CTX110, TARGETING CD19+ MALIGNANCIES.  Full Article

Crispr Therapeutics Provides Business Update And Reports Fourth Quarter And Full Year 2019 Financial Results
Thursday, 13 Feb 2020 

Feb 12 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.CRISPR THERAPEUTICS AG - QTRLY NET INCOME PER SHARE ATTRIBUTABLE TO COMMON SHAREHOLDERS - DILUTED $0.51.  Full Article

CRISPR Therapeutics Announces Pricing Of Public Offering Of Common Shares
Thursday, 21 Nov 2019 

Nov 20 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 4.25 MILLION COMMON SHARES PRICED AT $64.50PER SHARE.  Full Article

CRISPR Therapeutics Announces Proposed Public Offering Of Common Shares
Wednesday, 20 Nov 2019 

Nov 19 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.SAYS OFFERING 4.25 MILLION COMMON SHARES.  Full Article

CRISPR Therapeutics Reports Q3 Earnings Per Share $2.40
Monday, 28 Oct 2019 

Oct 28 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 2019 TOTAL COLLABORATION REVENUE $211.9 MILLION VERSUS $0.6 MILLION FOR Q3 2018.Q3 EARNINGS PER SHARE $2.40.CRISPR THERAPEUTICS - Q3 REVENUE INCREASE PRIMARILY DRIVEN BY COLLABORATION AGREEMENT WITH VERTEX.Q3 EARNINGS PER SHARE VIEW $-0.95, REVENUE VIEW $6.2 MILLION -- REFINITIV IBES DATA.  Full Article

Crispr Therapeutics And Bayer Announce Update On Casebia Therapeutics
Monday, 21 Oct 2019 

Oct 21 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AND BAYER ANNOUNCE AN UPDATE ON CASEBIA THERAPEUTICS.CRISPR THERAPEUTICS - CASEBIA THERAPEUTICS, A JV BETWEEN CRISPR THERAPEUTICS AND BAYER, WOULD OPERATE UNDER DIRECT MANAGEMENT OF CRISPR THERAPEUTICS.CRISPR THERAPEUTICS AG - CASEBIA THERAPEUTICS WOULD FOCUS ON DEVELOPMENT OF ITS LEAD PROGRAMS IN HEMOPHILIA, OPHTHALMOLOGY AND AUTOIMMUNE DISEASES.CRISPR THERAPEUTICS AG - BAYER WILL HAVE OPT-IN RIGHTS FOR TWO OF CASEBIA THERAPEUTICS' PRODUCTS AT IND SUBMISSION.  Full Article

CRISPR Therapeutics And KSQ Therapeutics Announce License Agreement To Advance Companies' Respective Cell Therapy Programs In Oncology
Tuesday, 15 Oct 2019 

Oct 15 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AND KSQ THERAPEUTICS ANNOUNCE LICENSE AGREEMENT TO ADVANCE COMPANIES’ RESPECTIVE CELL THERAPY PROGRAMS IN ONCOLOGY.CRISPR THERAPEUTICS AG - KSQ THERAPEUTICS TO RECEIVE NON-EXCLUSIVE ACCESS TO CERTAIN CRISPR IP FOR ITS AUTOLOGOUS CELL THERAPIES.CRISPR THERAPEUTICS AG - TO RECEIVE NON-EXCLUSIVE ACCESS TO CERTAIN KSQ IP FOR ITS ALLOGENEIC CAR-T PROGRAMS.CRISPR THERAPEUTICS AG - FINANCIAL TERMS OF AGREEMENT ARE NOT BEING DISCLOSED..  Full Article